Business
GW Pharmaceuticals’ CEO talks Epidiolex, future of cannabidiol medicine
The U.S. Food and Drug Administration could decide as early as June 27 whether Epidiolex, a CBD oral solution, could be prescribed to patients with rare epilepsy conditions.
